Authors:

Veny K Yantie, Ariawati K

Abstract:

“Hemophilia is an X-linked recessive disorder which is believed to affect approximately one in 5000-10.000 male birth. An inhibitor is a type of antibody. In hemophilia patients type A, B, and C are directly destroy factor VII, IX, and XI. The incidence of antibody development in hemophilia A is between 20% and 40%, hemophilia B inhibitors only 1 to 6 %. The presence of an inhibitor is usually confirmed using a specific blood test called the Bethesda inhibitor assay. The treatment of hemophilic bleeding in a person with an inhibitor can be a challenging experience. Patients hemophilia with inhibitor have poor prognostic. (MEDICINA 2012;43:31-36).”

Keywords

Keyword Not Available

Downloads:

Download data is not yet available.

References

References Not Available

PDF:

https://jurnal.harianregional.com/medicina/full-4948

Published

2021-11-09

How To Cite

K YANTIE, Veny; K, Ariawati. INHIBITOR IN HEMOPHILIA.Medicina, [S.l.], v. 43, n. 1, mar. 2013. ISSN 2540-8321. Available at: https://jurnal.harianregional.com/medicina/id-4948. Date accessed: 28 Aug. 2025.

Citation Format

ABNT, APA, BibTeX, CBE, EndNote - EndNote format (Macintosh & Windows), MLA, ProCite - RIS format (Macintosh & Windows), RefWorks, Reference Manager - RIS format (Windows only), Turabian

Issue

Vol 43 No 1 (2012): Januari 2012

Section

Articles

Creative Commons License This work is licensed under a Creative Commons Attribution 4.0 International License